Cardioembolic stroke diagnosis using blood biomarkers

Current Cardiology Reviews

Volumn 9, Issue 4, 2013, Pages 340-352

  Llombart, Víctor ^a,b,c   García Berrocoso, Teresa ^a,b,c   Bustamante, Alejandro ^a,b,c   Fernández Cadenas, Israel ^a,b,c   Montaner, Joan ^a,b,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Fundació per la Docència i Recerca MútuaTerrassa ^*  (Spain)

Author keywords

Atrial; Biomarker; Cardioembolic; Classification; Etiology; Fibrillation; MiRNA; Stroke

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; D DIMER; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICRORNA; SELECTIN; SMALL UNTRANSLATED RNA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD CLOTTING; CARDIOEMBOLIC STROKE; CELL DAMAGE; DISEASE CLASSIFICATION; ENDOTHELIUM CELL; FIBRINOLYSIS; GENE EXPRESSION; GENETICS; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; SECONDARY PREVENTION; TRANSCRIPTOMICS;

BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; GENETIC MARKERS; HUMANS; INFLAMMATION; MICRORNAS; POLYMORPHISM, GENETIC; STROKE; THROMBOSIS;

EID: 84895451946     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/1573403X10666140214122633     Document Type: Article

References (94)

1. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation 2013; 127(1): 143-52.
2. Kuklina EV, Tong X, George MG, Bansil P. Epidemiology and prevention of stroke: a worldwide perspective. Expert Rev Neurother 2012; 12(2): 199-208.
3. Mukherjee D, Patil CG. Epidemiology and the global burden of stroke. World Neurosurg 2011; 76(6 Suppl): S85-90.
4. Mohr JP, Caplan LR, Melski JW, et al. The Harvard Cooperative Stroke Registry: a prospective registry. Neurology 1978; 28(8): 754-62.
5. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24(1): 35-41.
6. Sacco RL, Ellenberg JH, Mohr JP, et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol 1989; 25(4): 382-90.
7. Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol 2005; 58(5): 688-97.
8. Ay H, Benner T, Arsava EM, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke 2007; 38(11): 2979-84.
9. Han SW, Kim SH, Lee JY, et al. A new subtype classification of ischemic stroke based on treatment and etiologic mechanism. Eur Neurol 2007; 57(2): 96-102.
10. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. Classification of stroke subtypes. Cerebrovasc Dis 2009; 27(5): 493-501.
11. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. New approach to stroke subtyping: the A-S-C-O (phenotypic) classification of stroke. Cerebrovasc Dis 2009; 27(5): 502-8.
12. Gao S, Wang YJ, Xu AD, Li YS, Wang DZ. Chinese ischemic stroke subclassification. Front Neurol 2011; 2: 6.
13. Lee SJ, Saver JL, Liebeskind DS, et al. Safety of intravenous fibrinolysis in imaging-confirmed single penetrator artery infarcts. Stroke 2010; 41(11): 2587-91.
14. Hsia AW, Sachdev HS, Tomlinson J, Hamilton SA, Tong DC. Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtype really matter? Neurology 2003; 61(1): 71-5.
15. Mustanoja S, Meretoja A, Putaala J, et al. Outcome by stroke etiology in patients receiving thrombolytic treatment: descriptive subtype analysis. Stroke 2011; 42(1): 102-6.
16. Singer OC, Kurre W, Humpich MC, et al. Risk assessment of symptomatic intracerebral hemorrhage after thrombolysis using DWI-ASPECTS. Stroke 2009; 40(8): 2743-8.
17. Saver JL. Improving reperfusion therapy for acute ischaemic stroke. J Thromb Haemost 2011; 9 Suppl 1: 333-43.
18. Wolf ME, Sauer T, Alonso A, Hennerici MG. Comparison of the new ASCO classification with the TOAST classification in a population with acute ischemic stroke. J Neurol 2012; 259(7): 1284-9.
19. Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol 1986; 43(1): 71-84.
20. García-Berrocoso T, Fernández-Cadenas I, Delgado P, Rosell A, Montane J. Blood biomarkers to identify ischemic stroke etiologies. Therapy 2010; 7(4): 337-53.
21. García-Berrocoso T, Fernández-Cadenas I, Delgado P, Rosell A, Montaner J. Blood biomarkers in cardioembolic stroke. Curr Cardiol Rev 2010; 6(3): 194-201.
22. Isenegger J, Meier N, Lämmle B et al. D-dimers predict stroke subtype when assessed early. Cerebrovasc Dis 2010; 29(1): 82-6.
23. Tombul T, Atbas C, Anlar O. Hemostatic markers and platelet aggregation factors as predictive markers for type of stroke and neurological disability following cerebral infarction. J Clin Neurosci 2005; 12(4): 429-34.
24. Montaner J, Perea-Gainza M, Delgado P, et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008; 39(8): 2280-7.
25. Alvarez-Perez FJ, Castelo-Branco M, Alvarez-Sabin J. Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke. J Neurol Neurosurg Psychiatr 2011; 82(9): 986-92.
26. Hirano K, Takashima S, Dougu N, et al. Study of hemostatic biomarkers in acute ischemic stroke by clinical subtype. J Stroke Cerebrovasc Dis 2012; 21(5): 404-10.
27. Fonseca AC, Matias JS, Pinho e Melo T, Falcão F, Canhão P, Ferro JM. N-terminal probrain natriuretic peptide as a biomarker of cardioembolic stroke. Int J Stroke 2011; 6(5): 398-403.
28. Naya T, Yukiiri K, Hosomi N, et al. Brain natriuretic peptide as a surrogate marker for cardioembolic stroke with paroxysmal atrial fibrillation. Cerebrovasc Dis 2008; 26(4): 434-40.
29. Shibazaki K, Kimura K, Iguchi Y, Okada Y, Inoue T. Plasma brain natriuretic peptide can be a biological marker to distinguish cardioembolic stroke from other stroke types in acute ischemic stroke. Intern Med 2009; 48(5): 259-64.
30. Yukiiri K, Hosomi N, Naya T, et al. Plasma brain natriuretic peptide as a surrogate marker for cardioembolic stroke. BMC Neurol 2008; 8: 45.
31. Rost NS, Biffi A, Cloonan L, et al. Brain natriuretic peptide predicts functional outcome in ischemic stroke. Stroke 2012; 43(2): 441-5.
32. Rodríguez-Yáñez M, Sobrino T, Blanco M, et al. High serum levels of pro-brain natriuretic peptide (pro BNP) identify cardioembolic origin in undetermined stroke. Dis Markers 2009; 26(4): 189-95.
33. Licata G, Tuttolomondo A, Di Raimondo D, Corrao S, Di Sciacca R, Pinto A. Immuno-inflammatory activation in acute cardioembolic strokes in comparison with other subtypes of ischaemic stroke. Thromb Haemost 2009; 101(5): 929-37.
34. Freestone B, Gustafsson F, Chong AY, et al. Influence of atrial fibrillation on plasma von willebrand factor, soluble E-selectin, and N-terminal pro B-type natriuretic peptide levels in systolic heart failure. Chest 2008; 133(5): 1203-8.
35. Folsom AR, Rosamond WD, Shahar E, et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999; 100(7): 736-42.
36. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GDO, Fowkes FGR. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007; 115(16): 2119-27.
37. Hanson E, Jood K, Karlsson S, Nilsson S, Blomstrand C, Jern C. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost 2011; 9(2): 275-81.
38. Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley TH Jr, Folsom AR. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study. Stroke 2006; 37(10): 2493-8.
39. Santamarina E, Penalba A, García-Berrocoso T, et al. Biomarker level improves the diagnosis of embolic source in ischemic stroke of unknown origin. J Neurol 2012; 259(12): 2538-45.
40. Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A, Licata G. Inflammation in ischemic stroke subtypes. Curr Pharm Des 2012; 18(28): 4289-310.
41. Luan Y, Guo Y, Li S, et al. Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease. Europace 2010; 12(12): 1713-8.
42. Freestone B, Chong AY, Nuttall S, Blann AD, Lip GYH. Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/ dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest 2007; 132(4): 1253-8.
43. Ehrlich JR, Kaluzny M, Baumann S, Lehmann R, Hohnloser SH. Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation. Clin Res Cardiol 2011; 100(11): 1029-36.
44. Yamauchi K, Furui H, Taniguchi N, Sotobata I. Plasma betathromboglobulin and platelet factor 4 concentrations in patients with atrial fibrillation. Jpn Heart J 1986; 27(4): 481-7.
45. Fu R, Wu S, Wu P, Qiu J. A study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation. Europace 2011; 13(1): 31-6.
46. Azzam H, Zagloul M. Elevated platelet microparticle levels in valvular atrial fibrillation. Hematology 2009; 14(6): 357-60.
47. Cengel A, Sahinarslan A, Biberoǧlu G, et al. Asymmetrical dimethylarginine level in atrial fibrillation. Acta Cardiol 2008; 63(1): 33-7.
48. Schulze F, Carter AM, Schwedhelm E, et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 2010; 208(2): 518-23.
49. Terruzzi A, Valente L, Mariani R, Moschini L, Camerlingo M. Creactive protein and aetiological subtypes of cerebral infarction. Neurol Sci 2008; 29(4): 245-9.
50. Yeh ETH, Khan BV. The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis. J Thromb Haemost 2006; 4(11): 2308-16.
51. Mullenix PS, Andersen CA, Starnes BW. Atherosclerosis as inflammation. Ann Vasc Surg 2005; 19(1): 130-8.
52. Alvarez-Perez FJ, Castelo-Branco M, Alvarez-Sabin J. Albumin level and stroke. Potential association between lower albumin level and cardioembolic aetiology. Int J Neurosci 2011; 121(1): 25-32.
53. Turgut B, Turgut N, Celik Y, Tekgündüz E, Pamuk GE, Demir M. Differences in platelet-leukocyte aggregates among subtypes of acute cerebral ischemia. J Neurol Sci 2011; 305(1-2): 126-30.
54. Cucchiara BL, Messe SR, Sansing L, et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke 2009; 40(7): 2332-6.
55. Yokota C, Minematsu K, Tomii Y et al. Low levels of plasma soluble receptor for advanced glycation end products are associated with severe leukoaraiosis in acute stroke patients. J Neurol Sci 2009; 287(1-2): 41-4.
56. Arboix A, Alió J. Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis. Curr Cardiol Rev 2010; 6(3): 150-61.
57. Arboix A, Alió J. Acute cardioembolic stroke: an update. Expert Rev Cardiovasc Ther 2011; 9(3): 367-79.
58. Jickling GC, Xu H, Stamova B, et al. Signatures of cardioembolic and large-vessel ischemic stroke. Ann Neurol 2010; 68(5): 681-92.
59. Becker RC. Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect. J Thromb Thrombolysis 2005; 19(1): 71-5.
60. Skoloudík D, Bar M, Sanák D, et al. D-dimers increase in acute ischemic stroke patients with the large artery occlusion, but do not depend on the time of artery recanalization. J Thromb Thrombolysis 2010; 29(4): 477-82.
61. Petzold A, Michel P, Stock M, Schluep M. Glial and axonal body fluid biomarkers are related to infarct volume, severity, and outcome. J Stroke Cerebrovasc Dis 2008; 17(4): 196-203.
62. Tuttolomondo A, Di Raimondo D, Di Sciacca R, et al. Fetuin-A and CD40 L plasma levels in acute ischemic stroke: Differences in relation to TOAST subtype and correlation with clinical and laboratory variables. Atherosclerosis 2010; 208(1): 290-6.
63. Osmancik P, Peroutka Z, Budera P, Herman D, Stros P, Straka Z. Changes in cytokine concentrations following successful ablation of atrial fibrillation. European Cytokine Network. 2010; 21(4): 278-84.
64. Shin SY, Yong HS, Lim HE, et al. Total and interatrial epicardial adipose tissues are independently associated with left atrial remodeling in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2011; 22(6): 647-55.
65. Shimano M, Shibata R, Tsuji Y, et al. Circulating adiponectin levels in patients with atrial fibrillation. Circ J 2008; 72(7): 1120-4.
66. Choudhury A, Freestone B, Patel J, Lip GYH. Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation: a link among platelet activation, angiogenesis, and thrombosis? Chest 2007; 132(6): 1913-9.
67. Falcone C, Buzzi MP, D'Angelo A, et al. Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation. Int J Immunopathol Pharmacol 2010; 23(3): 917-25.
68. Ellinor PT, Low AF, Macrae CA. Reduced apelin levels in lone atrial fibrillation. Eur Heart J 2006; 27(2): 222-6.
69. Choudhury A, Chung I, Blann AD, Lip GYH. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet Pselectin as indexes of platelet function in atrial fibrillation: a comparison of "healthy control subjects" and "disease control subjects" in sinus rhythm. J Am Coll Cardiol 2007; 49(19): 1957-64.
70. Marín F, Roldán V, Climent V, Garcia A, Marco P, Lip GYH. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke 2003; 34(5): 1181-6.
71. Kalogeropoulos AS, Tsiodras S, Rigopoulos AG, et al. Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation. BMC Cardiovasc Disord 2011; 11: 77.
72. Gartner W, Zierhut B, Mineva I, et al. Brain natriuretic peptide correlates with the extent of atrial fibrillation-associated silent brain lesions. Clin Biochem 2008; 41(18): 1434-9.
73. Schnabel RB, Larson MG, Yamamoto JF, et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol 2009; 104(1): 92-6.
74. Behnes M, Hoffmann U, Lang S, et al. Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure. Clin Res Cardiol 2011; 100(4): 335-42.
75. Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation 2012; 125(13): 1605-16.
76. Scridon A, Morel E, Nonin-Babary E, Girerd N, Fernandez C, Chevalier P. Increased intracardiac vascular endothelial growth factor levels in patients with paroxysmal, but not persistent atrial fibrillation. Europace 2012; 14(7): 948-53.
77. Jickling GC, Stamova B, Ander BP, et al. Prediction of cardioembolic, arterial, and lacunar causes of cryptogenic stroke by gene expression and infarct location. Stroke 2012; 43(8): 2036-41.
78. Jickling GC, Stamova B, Ander BP, et al. Profiles of lacunar and nonlacunar stroke. Ann Neurol 2011; 70(3): 477-85.
79. Reid G, Kirschner MB, Van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011; 80(2): 193-208.
80. Gan CS, Wang CW, Tan KS. Circulatory microRNA-145 expression is increased in cerebral ischemia. Genet Mol Res 2012; 11(1): 147-52.
81. Zeng L, Liu J, Wang Y, et al. MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia. Front Biosci (Elite Ed) 2011; 3: 1265-72.
82. Tan KS, Armugam A, Sepramaniam S, et al. Expression profile of MicroRNAs in young stroke patients. PLoS ONE 2009; 4(11): e7689.
83. Wang Z, Lu Y, Yang B. MicroRNAs and atrial fibrillation: new fundamentals. Cardiovasc Res 2011; 89(4): 710-21.
84. Liu Z, Zhou C, Liu Y, et al. The expression levels of plasma micoRNAs in atrial fibrillation patients. PLoS ONE 2012; 7(9): e44906.
85. Adam O, Löhfelm B, Thum T, et al. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol 2012; 107(5): 278.
86. Bellenguez C, Bevan S, Gschwendtner A, et al. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet 2012; 44(3): 328-33.
87. Tuttolomondo A, Di Raimondo D, Forte GI, et al. Single nucleotide polymorphisms (SNPs) of pro-inflammatory/anti-inflammatory and thrombotic/fibrinolytic genes in patients with acute ischemic stroke in relation to TOAST subtype. Cytokine 2012; 58(3): 398-405.
88. Jannes J, Hamilton-Bruce MA, Pilotto L, et al. Tissue plasminogen activator-7351C/T enhancer polymorphism is a risk factor for lacunar stroke. Stroke 2004; 35(5): 1090-4.
89. Belfer I, Wu T, Hipp H, et al. Linkage of large-vessel carotid atherosclerotic stroke to inflammatory genes via a systematic screen. Int J Stroke 2010; 5(3): 145-51.
90. Kostulas N, Nikolaos K, Markaki I, et al. Common CCR 5 polymorphism in stroke: the CCR 5 delta32 polymorphism differentiates cardioembolism from other aetiologies of ischaemic cerebrovascular diseases. Scand J Immunol 2009; 70(5): 475-80.
91. Dawson J, Walters M, Delles C, Mischak H, Mullen W. Urinary proteomics to support diagnosis of stroke. PLoS ONE 2012; 7(5): e35879.
92. Dayon L, Turck N, Garcí-Berrocoso T, et al. Brain extracellular fluid protein changes in acute stroke patients. J Proteome Res 2011; 10(3): 1043-51.
93. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27(2): 157-72.
94. Pickering JW, Endre ZH. New metrics for assessing diagnostic potential of candidate biomarkers. Clin J Am Soc Nephrol 2012; 7(8): 1355-64.